These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 21152452)
21. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Hampel H; Shen Y Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117 [TBL] [Abstract][Full Text] [Related]
22. [Alzheimer's disease: from brain lesions to new drugs]. Forette F; Hauw JJ Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689 [TBL] [Abstract][Full Text] [Related]
23. (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor. Cole DC; Stock JR; Kreft AF; Antane M; Aschmies SH; Atchison KP; Casebier DS; Comery TA; Diamantidis G; Ellingboe JW; Harrison BL; Hu Y; Jin M; Kubrak DM; Lu P; Mann CW; Martone RL; Moore WJ; Oganesian A; Riddell DR; Sonnenberg-Reines J; Sun SC; Wagner E; Wang Z; Woller KR; Xu Z; Zhou H; Jacobsen JS Bioorg Med Chem Lett; 2009 Feb; 19(3):926-9. PubMed ID: 19097890 [TBL] [Abstract][Full Text] [Related]
24. The structure and function of Alzheimer's gamma secretase enzyme complex. Krishnaswamy S; Verdile G; Groth D; Kanyenda L; Martins RN Crit Rev Clin Lab Sci; 2009; 46(5-6):282-301. PubMed ID: 19958215 [TBL] [Abstract][Full Text] [Related]
25. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. Citron M Trends Pharmacol Sci; 2004 Feb; 25(2):92-7. PubMed ID: 15102495 [TBL] [Abstract][Full Text] [Related]
26. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. Kerr ML; Small DH J Neurosci Res; 2005 Apr; 80(2):151-9. PubMed ID: 15672415 [TBL] [Abstract][Full Text] [Related]
27. Alzheimer's disease therapeutics: new approaches to an ageing problem. Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347 [TBL] [Abstract][Full Text] [Related]
28. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404 [TBL] [Abstract][Full Text] [Related]
29. Aspartic proteases involved in Alzheimer's disease. Schmidt B Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808 [TBL] [Abstract][Full Text] [Related]
30. LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Majercak J; Ray WJ; Espeseth A; Simon A; Shi XP; Wolffe C; Getty K; Marine S; Stec E; Ferrer M; Strulovici B; Bartz S; Gates A; Xu M; Huang Q; Ma L; Shughrue P; Burchard J; Colussi D; Pietrak B; Kahana J; Beher D; Rosahl T; Shearman M; Hazuda D; Sachs AB; Koblan KS; Seabrook GR; Stone DJ Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17967-72. PubMed ID: 17098871 [TBL] [Abstract][Full Text] [Related]
31. Secretases as therapeutic targets for Alzheimer's disease. Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746 [TBL] [Abstract][Full Text] [Related]
32. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Mullane K; Williams M Biochem Pharmacol; 2013 Feb; 85(3):289-305. PubMed ID: 23178653 [TBL] [Abstract][Full Text] [Related]
33. Current perspectives on pharmacotherapy of Alzheimer's disease. Chopra K; Misra S; Kuhad A Expert Opin Pharmacother; 2011 Feb; 12(3):335-50. PubMed ID: 21222549 [TBL] [Abstract][Full Text] [Related]
34. Why as a medicinal chemist I am not optimistic about the possibility of finding, in a reasonable timeframe, small-molecule drugs capable of curing the evolution of Alzheimer's disease. Kraus JL ChemMedChem; 2012 Mar; 7(3):357-8. PubMed ID: 21990179 [TBL] [Abstract][Full Text] [Related]
35. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease. Adlard PA; James SA; Bush AI; Masters CL Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094 [TBL] [Abstract][Full Text] [Related]
36. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Cummings J Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622 [No Abstract] [Full Text] [Related]
37. Investigational drugs in Alzheimer's disease: current progress. Berk C; Paul G; Sabbagh M Expert Opin Investig Drugs; 2014 Jun; 23(6):837-46. PubMed ID: 24702504 [TBL] [Abstract][Full Text] [Related]
38. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity. Beierlein JM; McNamee LM; Walsh MJ; Ledley FD Clin Ther; 2015 Aug; 37(8):1643-51.e3. PubMed ID: 26243074 [TBL] [Abstract][Full Text] [Related]
39. Cutting-edge patents in Alzheimer's disease drug discovery: anticipation of potential future treatments. Lecanu L; Papadopoulos V Recent Pat CNS Drug Discov; 2007 Jun; 2(2):113-23. PubMed ID: 18221222 [TBL] [Abstract][Full Text] [Related]
40. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. Bachurin SO; Bovina EV; Ustyugov AA Med Res Rev; 2017 Sep; 37(5):1186-1225. PubMed ID: 28084618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]